GNRHR

Gonadotropin-releasing hormone receptor · P30968 · GNRHR on Sugi Atlas →

23,637 patent compounds predicted against GNRHR, 14,149 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL126814	1.00	20/20
Trifluoroacetic Acid (SCHEMBL127332)	1.00	20/20
Trifluoroacetic Acid (SCHEMBL127333)	1.00	20/20
SCHEMBL128053	1.00	20/20
SCHEMBL128054	1.00	20/20
Trifluoroacetic Acid (SCHEMBL128720)	1.00	20/20
Trifluoroacetic Acid (SCHEMBL128721)	1.00	20/20
Trifluoroacetic Acid (SCHEMBL129056)	1.00	20/20
Trifluoroacetic Acid (SCHEMBL129057)	1.00	20/20
Trifluoroacetic Acid (SCHEMBL129551)	1.00	20/20
Trifluoroacetic Acid (SCHEMBL129552)	1.00	20/20
SCHEMBL208907	1.00	20/20
Sufugolix (SCHEMBL209021)	1.00	20/20
Relugolix (SCHEMBL778416)	1.00	20/20
SCHEMBL778510	1.00	20/20
SCHEMBL778579	1.00	20/20
SCHEMBL778883	1.00	20/20
SCHEMBL779349	1.00	20/20
SCHEMBL779673	1.00	20/20
SCHEMBL779729	1.00	20/20

Clinical trials — most relevant to GNRHR by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Effectiveness and Safety of the Prolonged Down-regulation Protocol for Controlled Ovarian Hyperstimulation	PHASE4	UNKNOWN
Hormonal Effects of the Oral Gonadotropin Releasing Hormone (GnRH) Antagonist at Different Periods of the Menstrual Cycle	PHASE4	UNKNOWN
Investigating the Potential Role of Aerosolized Retinoic Acid, a Potent Vitamin A Metabolite for Treating COVID-19 Anosmia and Retinoic Acid Insufficiency .A Novel Approach for Regaining Sense of Smell.	PHASE4	UNKNOWN
INTEnsity of ovariaN Stimulation and Embryo Quality	PHASE4	COMPLETED
Evaluate the Efficacy and Safety of DWJ108J	PHASE3	UNKNOWN
Study of Leuprolide Acetate Injectable Suspension in the Treatment of Central Precocious Puberty	PHASE3	COMPLETED
GnRH Antagonist Versus GnRH Agonist in Polycystic Ovary Syndrome During in Vitro Fertilization - Embryo Transfer	PHASE3	COMPLETED
Combination of Gonadotropin-releasing Hormone Agonist and Human Chorionic Gonadotropin Triggered by Normal Responder in GnRH-antagonist Cycles	PHASE3	UNKNOWN
COMPARING TWO PROTOCOLS FOR FINAL OOCYTE MATURATION IN POOR RESPONDERS UNDERGOING GnRH-ANTAGONIST ICSI CYCLES	PHASE3	UNKNOWN
A Pharmacodynamic Study of Leuprorelin Gelatin-Free Formulation in Female Subjects With Uterine Fibroids.	PHASE2	COMPLETED
TRial on the Endocrine Activity of Neoadjuvant Degarelix	PHASE2	COMPLETED
Pulsatile GnRH in Anovulatory Infertility	PHASE2	UNKNOWN
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer	PHASE2	COMPLETED
Lutropin Alfa in Women at Risk of Poor Response	PHASE2	COMPLETED
Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer	PHASE1	RECRUITING
Studying the Effects of 7 Days of Gonadotropin Releasing Hormone (GnRH) Treatment in Men With Hypogonadism	PHASE1	COMPLETED
Comparing Ovarian Stimulation for Assisted Reproduction With Two Different Forms of Pituitary Suppression	nan	COMPLETED
Extra Luteinizing Hormone Improve Embryo Quality in IVF Patients With Low LH During Long GnRH-Agonist Treatment	nan	RECRUITING
Time-Lapse Incubation for Embryo Culture - Morphokinetics and Environmental Stability	nan	UNKNOWN
Effect of GnRH Agonist Treatment Protocols on Ovarian Reserve	nan	COMPLETED
Inherited Reproductive Disorders	nan	RECRUITING
Progesterone Primed Ovarian Stimulation Versus GnRH Antagonist Protocols in Women With Polycystic Ovarian Syndrome	nan	COMPLETED
Genetic Variation in Gonadotropin and Gonadotropin Receptor Genes and Suboptimal Response	nan	COMPLETED
Ovarian Response Prediction in In Vitro Fertilization (IVF) Patients	nan	COMPLETED
Perception of Cohesion Within a Relationship (Dyadic Adjustment) on the Quality of Life of Patients With Prostate Cancer With Gonadotropin-releasing Hormone.	nan	COMPLETED
OvS Breast: Ovarian Suppression in Breast Cancer Interventions	nan	RECRUITING
Comparison of 2 Ovarian Stimulation Protocols for Women With Low Ovarian Reserve	nan	UNKNOWN
Hormonal Regulation of Puberty and Fertility	nan	COMPLETED
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients	nan	UNKNOWN
Effects of SNP of GnRH Receptor Genes in IVF Patients	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a GNRHR binder may also engage these)

Protein	Name	Similarity
Q9MZI6	—	1.000	Q9MZI6 →
P32237	—	1.000	P32237 →
P32236	—	1.000	P32236 →
P49922	—	1.000	P49922 →
Q19PY9	—	1.000	Q19PY9 →
P30969	—	1.000	P30969 →
O18821	—	1.000	O18821 →
Q01776	—	1.000	Q01776 →
Q8CH60	—	0.996	Q8CH60 →
Q9TTI8	—	0.996	Q9TTI8 →
Q90252	—	0.964	Q90252 →
O42329	—	0.963	O42329 →
Q90334	—	0.961	Q90334 →
Q95JG1	—	0.960	Q95JG1 →
Q96P88	—	0.958	Q96P88 →
Q95MH6	—	0.955	Q95MH6 →
Q8BZP8	—	0.954	Q8BZP8 →
Q95MG6	—	0.952	Q95MG6 →
Q56H79	—	0.952	Q56H79 →
P0C0L6	—	0.952	P0C0L6 →
Q5QNP2	—	0.951	Q5QNP2 →
NPSR1	Neuropeptide S receptor	0.947	landscape →
O02300	—	0.947	O02300 →
Q8K418	—	0.946	Q8K418 →
Q5QD16	—	0.946	Q5QD16 →
Q7T3Q7	—	0.946	Q7T3Q7 →
Q8BZ39	—	0.945	Q8BZ39 →
O97967	—	0.945	O97967 →
Q9P1P5	—	0.945	Q9P1P5 →
Q923Y7	—	0.945	Q923Y7 →